Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Can Mediate Degradation of the Low Density Lipoprotein Receptor-Related Protein 1 (LRP-1)

Proprotein Convertase Subtilisin/Kexin Type 9 Deficiency Reduces Melanoma Metastasis in Liver

(2015) Xiaowei Sun et al.   NEOPLASIA

PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling

(2012) Kai Kysenius et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Description of a Large Family with Autosomal Dominant Hypercholesterolemia Associated with theAPOEp.Leu167del Mutation

(2012) Marie Marduel et al.   HUMAN MUTATION

The M2 Module of the Cys-His-rich Domain (CHRD) of PCSK9 Protein Is Needed for the Extracellular Low-density Lipoprotein Receptor (LDLR) Degradation Pathway

(2012) Yascara Grisel Luna Saavedra et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Loss- and Gain-of-function PCSK9 Variants

(2012) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial

(2012) Evan A Stein et al.   LANCET

LDL Cholesterol: The Lower the Better

(2012) Seth S. Martin et al.   MEDICAL CLINICS OF NORTH AMERICA

The biology and therapeutic targeting of the proprotein convertases

(2012) Nabil G. Seidah et al.   NATURE REVIEWS DRUG DISCOVERY

Annexin A2 Is a Natural Extrahepatic Inhibitor of the PCSK9-Induced LDL Receptor Degradation

(2012) Nabil G. Seidah et al.   PLoS One

Circulating Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) Regulates VLDLR Protein and Triglyceride Accumulation in Visceral Adipose Tissue

(2011) Anna Roubtsova et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Low-density lipoprotein receptor-related protein 1: new functions for an old molecule

(2011) Massimo Franchini et al.   CLINICAL CHEMISTRY AND LABORATORY MEDICINE

Signaling through LRP1: Protection from atherosclerosis and beyond

(2010) Philippe Boucher et al.   BIOCHEMICAL PHARMACOLOGY

Effects of the Prosegment and pH on the Activity of PCSK9

(2010) Suzanne Benjannet et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A Two-step Binding Model of PCSK9 Interaction with the Low Density Lipoprotein Receptor

(2010) Taichi Yamamoto et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Disrupted recycling of the low density lipoprotein receptor by PCSK9 is not mediated by residues of the cytoplasmic domain

(2010) Thea Bismo Strøm et al.   MOLECULAR GENETICS AND METABOLISM

Dissection of the Endogenous Cellular Pathways of PCSK9-induced Low Density Lipoprotein Receptor Degradation

(2009) Steve Poirier et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Implications multiples du récepteur LRP-1 dans la progression tumorale

(2009) B. Langlois et al.   PATHOLOGIE BIOLOGIE

PCSK9 as a therapeutic target of dyslipidemia

(2008) Nabil G Seidah   EXPERT OPINION ON THERAPEUTIC TARGETS

Proprotein convertase subtilisin/kexin type 9 (PCSK9): Hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

(2008) Ahmed Zaid et al.   HEPATOLOGY

Annexin A2 Is a C-terminal PCSK9-binding Protein That Regulates Endogenous Low Density Lipoprotein Receptor Levels

(2008) Gaétan Mayer et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

LDL Receptor-Related Protein 1: Unique Tissue-Specific Functions Revealed by Selective Gene Knockout Studies

(2008) Anna P. Lillis et al.   PHYSIOLOGICAL REVIEWS

Molecular basis for LDL receptor recognition by PCSK9

(2008) H. J. Kwon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor

(2008) D.-W. Zhang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA